Oncology

A review of clinical trials and genetic, immune, and environmental factors revealed that Asian patients with advanced HER2-negative gastric cancer generally experience higher response rates and longer survival with immunotherapy than non-Asian patients.

A March 2026 study found that U.S. cancer patients with hypertension, hyperlipidemia or diabetes face consistently higher healthcare costs, which increased steadily from 2012 to 2018, dropped during the COVID-19 pandemic and remain elevated compared with patients without these conditions.

CLDN18.2-high gastroesophageal cancer appears more common and could predict a stronger HER2 therapy benefit but a weaker immunotherapy response.

A study across B-cell lymphomas shows zanubrutinib delivers higher complete and overall response rates than acalabrutinib or ibrutinib, guiding BTK inhibitor choice.

The decision to withdraw the cancer drug Tazverik from the market was based on emerging data from a trial showing there is a risk of secondary hematological malignancies.

FDA reviews tirabrutinib for relapsed/refractory primary CNS lymphoma under accelerated approval, with promising phase 2 response rates and a Dec. 2026 decision.

Real-world China study uses Markov modeling to show surgery may beat radiotherapy on cost per QALY for ESCC, despite higher upfront costs.

COVID-19 care disruptions cut U.S. one-year cancer survival, adding 17,390 deaths; see which cancers and groups were hit hardest.

Study finds transfusion access drives hospice choices in advanced blood cancers, urging new models that offer palliative transfusions with comfort care.

People taking glucagon-like peptide 1 (GLP-1) drugs were 36% less likely to develop colorectal cancer than those taking aspirin, according to a real-world, head-to-head study.

New research reveals how gastric cancer cells exploit WNT signaling for growth, revealing potential treatment targets to combat this deadly disease.

MHE has a conversation with Renuka Iyer, M.D., who became CMO of NCCN in early December. Iyer is aiming to enhance evidence-based cancer care and expand guidelines for rare cancers and diverse populations.

The medical director of The US Oncology Network discusses adherence to clinical pathways, CAR-T therapy and concerns about the consequences of drug price negotiation under the Inflation Reduction Act.

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for improved dietary quality for prevention.

ASTRO's new guidelines enhance radiation therapy strategies for gastric cancer, improving treatment outcomes and patient care across various stages of the disease.

GLP-1 receptor agonists significantly lower five-year mortality in highly obese colon cancer patients, highlighting potential benefits beyond weight loss and inflammation reduction.

Consistent moderate physical activity significantly reduces the risk of digestive system cancers, highlighting the importance of long-term exercise for prevention.

New findings from the MATTERHORN trial reveal durvalumab combined with FLOT chemotherapy significantly improves survival in early-stage gastric cancer patients.

New research clarifies the definition of "cure" in stage II and III colon cancer, highlighting a six-year milestone for patient reassurance and care efficiency.

The Chinorec trial reveals that combining Yervoy and Opdivo with chemoradiotherapy is safe for rectal cancer, though response rates remain unchanged.

Expedited regulatory paths transform colorectal cancer treatment, enhancing access but creating challenges in clinical evidence and payer decisions.